人工智能驱动的临床决策支持系统在欧洲糖尿病护理中的应用:基于德尔菲法的共识路线图
欧洲糖尿病论坛(EUDF)工作组通过系列会议审查AI驱动临床决策支持系统(AI-CDSS)在糖尿病护理中的未满足需求,并采用名义群体技术和德尔菲法达成14条推荐,以推动AI-CDSS安全有效地进入临床实践。
要点
- AI-CDSS有望减少治疗惰性并优化临床结局,但监管流程需适应可自适应变化的系统。
- EUDF工作组通过德尔菲法形成14条推荐,以促进AI-CDSS在糖尿病护理中的安全有效实施。
- 推荐关注初级保健医护人员需求,他们承担多数糖尿病护理工作。
核心结论
- EUDF工作组认为AI-CDSS将为糖尿病患者带来获益,但将其移入实际临床空间存在明确挑战。
- 为鼓励关于如何安全有效实现这一目标的讨论,工作组通过名义群体技术和德尔菲法达成14条推荐。
研究设计与样本
- 欧洲糖尿病论坛(EUDF)召集工作组,通过系列虚拟和面对面会议(包括邮件沟通)审查AI技术在糖尿病护理中实施的未满足需求。
- 工作组基于现有证据,采用名义群体技术和德尔菲方法学达成14条推荐。
主要发现
- AI用于改善糖尿病患者的诊断、评估和治疗,有潜力推动糖尿病护理范式转变,同时最小化治疗惰性和优化临床结局。
- 对AI驱动技术的开发和实施监管流程是否适用于可能适应新数据并改变其原始性能特征的系统存在担忧。
- 工作组审查了当前和预测的AI-CDSS背景下良好糖尿病护理的关键目标,包括患者结局、个性化医疗目标以及对指南驱动服务和医护人员的影响。
- 过程涵盖了将承担多数糖尿病护理的初级保健医护人员的需求。
- 制定足够稳健且包容AI的监管概念和流程被视为结局的核心。
关键数值与推荐
- 工作组通过名义群体技术和德尔菲方法学达成14条推荐。
临床怎么用
- AI-CDSS可辅助医护人员和糖尿病患者在护理点进行临床决策,但需关注监管流程对自适应系统的适应性。
- 实施应考虑初级保健医护人员的需求,他们承担多数糖尿病护理。
局限性
- 原文未报告具体研究样本量、数据细节或推荐的具体内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of artificial intelligence (AI) to improve the diagnosis, assessment and treatment of people with diabetes has the potential to drive a paradigm shift in diabetes care, both minimising treatment inertia and optimising clinical outcomes. This is a significant opportunity, given the predicted increase in the burden of diabetes over the next 20 years. However, there are concerns that regulatory processes for development and implementation of AI-driven technologies are not adequate for systems that may adapt to new data and change from their original performance characteristics as evaluated. The European Diabetes Forum (EUDF) convened a working group to review and investigate the unmet needs around implementation of AI technology in diabetes care. The working group developed the framework and focus of the accompanying analysis through a series of virtual and face-to-face meetings, including email conversations. The working group examined the key objectives for good diabetes care in the context of current and predicted AI-driven clinical decision support systems (AI-CDSS), including the outcomes for people with diabetes, the goals for personalised medicine and the implications for guideline-driven diabetes services and healthcare professionals. The process covered the needs of primary care healthcare professionals, who will shoulder the majority of diabetes care. The challenge of developing regulatory concepts and processes that are sufficiently robust to be AI inclusive was considered as central to the outcomes. Based on the available evidence, the EUDF working group believes that AI-CDSS will deliver benefits for people with diabetes, although there are clear challenges to moving AI-CDSS into the practical clinical space. To encourage debate on how this can be achieved safely and effectively, at the conclusion of the process a series of 14 recommendations was agreed using a nominal group technique and Delphi methodology, which are discussed in context in this article.
引用
- Bajramagic M, Battelino T, Cos X, et al. Artificial intelligence-driven clinical decision support systems to assist healthcare professionals and people with diabetes in Europe at the point of care: a Delphi-based consensus roadmap. Diabetologia. 2025. PMID: 41247494. doi:10.1007/s00125-025-06601-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。